Pomerantz Law Firm Announces Class Action Against PROCEPT BioRobotics Corporation Amid Investors' Concerns

Investor Alert: Class Action Against PROCEPT BioRobotics

Pomerantz LLP has initiated a class action lawsuit targeting PROCEPT BioRobotics Corporation, a firm specializing in medical robotics. This legal move responds to mounting concerns from investors regarding potential securities fraud and deceptive business practices.

Investors who have suffered losses due to their investments in PROCEPT are encouraged to contact Pomerantz to participate in this class action. The deadline to apply as Lead Plaintiff is September 22, 2026. Interested individuals can reach out to Danielle Peyton via email at [email protected] or call at 646-581-9980.

Background on PROCEPT BioRobotics

In recent earnings reports, particularly those dated August 6 and November 4, 2025, PROCEPT’s financial performance raised eyebrows. During the second fiscal quarter of 2025, the company reported just 12,750 handpiece sales in the U.S., falling short of expectations. CFO Kevin Waters cautioned that anticipated shipments for the upcoming quarter might also be below analysts’ forecasts, indicating a possible 25% increase in sales needed for the annual target.

Compounding these matters, then-CEO Reza Zadno announced cuts to the role of Chief Commercial Officer, a strategic decision aimed at improving commercial execution amid sales struggles. The market reacted swiftly, marking a 16% drop in PROCEPT's stock price within two days following this revelation.

Later, on November 4, 2025, the company's subsequent earnings report showed yet another downturn, with handpiece sales totaling just 13,225 units, which again missed guidance. CFO Waters projected a downward revision of annual sales from 53,000 units to 52,000, sparking further concerns about inventory management within the company. CEO Larry L. Wood admitted to challenges in handling customer inventory levels, prompting further stock depreciation of over 10%.

Financial Disclosures and Stock Impact

The most alarming news transpired on February 25, 2026, when quarterly earnings revealed a staggering drop in handpiece sales, recording just 9,400 units sold, a nearly 30% decline from the previous quarter. This prompted a devastating 18% dip in share prices over just two days of trading, raising questions about the company’s stability and the transparency of its financial disclosures.

As a firm known for its commitment to representing shareholders in class action lawsuits, Pomerantz LLP has a long legacy, tracing its roots back over 85 years. It has secured substantial recoveries for victims of corporate wrongdoing, including securities fraud and fiduciary breaches. The firm’s founder, Abraham L. Pomerantz, was pivotal in shaping class action law and continues to resonate within the practice today.

For those affected and seeking restitution, joining this class action may provide an avenue to recover losses. Full details of the complaint and the opportunity to join can be found on Pomerantz’s website, www.pomerantzlaw.com.

The upcoming court actions represent a critical juncture for stakeholders in PROCEPT BioRobotics. Collectively, affected investors can amplify their voices and pursue potential recovery for the ongoing misleading business activities.

Conclusion

As this situation unfolds, investors must remain vigilant and informed. The proactive measures by law firms like Pomerantz LLP highlight the importance of accountability in corporate governance.

If you believe that you have been adversely affected by your investment in PROCEPT, reaching out to Pomerantz is advisable, as legal action looms and the window for joining the class action may close soon.